title: One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
abstract: OBJECTIVE
  To assess the 1-year outcome of half-dose verteporfin photodynamic therapy (PDT) for patients with chronic central serous chorioretinopathy (CSC).
  
  
  METHODS
  Retrospective, interventional case series with no controls.
  
  
  METHODS
  A total of 204 eyes of 204 patients with chronic CSC were studied.
  
  
  METHODS
  Fluorescein angiography (FA) and indocyanine green angiography (ICGA) were performed before PDT. The best-corrected visual acuities (BCVAs) were measured and optical coherence tomography was performed before and 1, 3, 6, 9, and 12 months after PDT.
  
  
  METHODS
  The main outcome measures were the resolution of the serous retinal detachment (SRD), changes in BCVA, and ocular and systemic complications at 12 months.
  
  
  RESULTS
  A total of 182 of 204 eyes (89.2%) had complete resolution of the SRD at 12 months after the PDT. Eleven eyes (5.4%) had a persistent SRD throughout the follow-up period, and 12 eyes (5.9%) had a recurrence of the SRD after an earlier resolution. One of the 12 eyes had a spontaneous resolution of the SRD 6 months after PDT. The mean±standard deviation BCVA in logarithm of the minimum angle of resolution (logMAR) units significantly improved from 0.11±0.25 before to 0.07±0.23 at 1 month, 0.02±0.23 at 3 months, 0.01±0.23 at 6 months, 0.00±0.24 at 9 months, and -0.01±0.22 at 12 months (P<0.0001). The eyes with an SRD at 12 months were more likely to have an intermediate hyperfluorescence on ICGA (chi-square test, P<0.001) and poorer BCVA before the half-dose PDT (Student t test, P=0.04) than those without SRD at 12 months. None of the patients developed any systemic complications or experienced any severe visual reduction after the half-dose PDT. However, polypoidal lesion appeared in 1 eye 8 months after the PDT.
  
  
  CONCLUSIONS
  Half-dose PDT is an effective and safe method to treat eyes with chronic CSC with an SRD. The CSC resolved and the BCVA improved significantly after PDT. Half-dose PDT was less effective for cases without intense hyperpermeability on ICGA and those with lower BCVA before the PDT.
authors.affiliation: Department of Ophthalmology, Surugadai Nihon University Hospital, Tokyo, Japan.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Fujita
authors.affiliation: Department of Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kanagawa, Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Imamura
authors.affiliation: Department of Ophthalmology, Surugadai Nihon University Hospital, Tokyo, Japan; Department of Ophthalmology, Teikyo University School of Medicine, University Hospital Itabashi, Tokyo, Japan. Electronic address: shinodak@med.teikyo-u.ac.jp.
authors.forename: Kei
authors.initials: K
authors.lastname: Shinoda
authors.affiliation: Department of Ophthalmology, Teikyo University School of Medicine, University Hospital Itabashi, Tokyo, Japan.
authors.forename: Celso Soiti
authors.initials: CS
authors.lastname: Matsumoto
authors.affiliation: Department of Ophthalmology, Surugadai Nihon University Hospital, Tokyo, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Mizutani
authors.affiliation: Department of Ophthalmology, Iwate Medical University, School of Medicine, Morioka, Japan.
authors.forename: Kouhei
authors.initials: K
authors.lastname: Hashizume
authors.affiliation: Department of Ophthalmology, Teikyo University School of Medicine, University Hospital Itabashi, Tokyo, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizota
authors.affiliation: Department of Ophthalmology, Surugadai Nihon University Hospital, Tokyo, Japan.
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Yuzawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage*; D012163:Retinal Detachment / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green